Barbara Sennino
Vice President, Early Development 3T Biosciences
Dr. Barbara Sennino is Senior Vice President and Head of Early Development at 3T Biosciences and oversees the preclinical and translational studies for the development of bispecific T cell engagers. Dr. Sennino is a seasoned expert in cancer immunotherapy, with over 10 years of experience in biotechnology companies. Her focus has been on developing innovative biologics, T cell therapies, and viral-based immunotherapies. She is particularly interested in exploring preclinical models, including patient-derived organoids, to enhance the prediction of clinical outcomes. Dr. Sennino holds a PhD in Biomedical Sciences from Italy and completed postdoctoral training at UCSF.
Seminars
Thursday 29th January 2026
Applying In Vitro Tissue Models to Evaluate Target Expression & Anticipate Safety of Bispecific T Cell Engagers
3:30 pm
- Exploring tumor models in vitro to assess target engagement, cytotoxicity, and mechanistic outcomes beyond primary tumor efficacy
- Profiling target expression across tissues to map potential off-tumor effects and guide tissue panel selection
- Alternative in vitro safety models to anticipate potential toxicity liabilities
